rheumatoid arthritis
Conditions
Interventions
RA patients with medium disease activity are treated with 200mg of CZP (loading dose method is ommited)
Sponsors
Saitama East Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients are fulfilled ACR(1987) or ACR/EULAR classification criteria for rheumatoid arthritis and are diagnosed as RA. 2.Patients have never treated with any biologics. 3.Before CPZ treatment,the dose and method of DMARD have not changed at leaset 8 weeks. 4.Before CPZ treatment,the dose and method of NSAIDs have not changed at leaset 4 weeks. 5.Before CPZ treatment,the dose and method of glucocorticoid have not changed at leaset 4 weeks.Patiennts are treated with prednisolone of 10mg/day or thess than 10mg/day. 6.The patients have swollen joints of 6 or less than 6 joints and have tender joints of 6 or less than 6 joints.
Exclusion criteria
Exclusion criteria: 1.Patients have other rheumatic diseases. 2. Patients have malignant disorders in recent 5 years. 3.Patients have a risk for tuberculosis. 4.Patients who develpoprd bacterial infection and antibiotics were administrated within 30 days after first CPZ treatment. 5.Drug or alcohol addiction or abusers. 6.Patients who are not able to be adequately evaluated in this study. 7.Patients who have Type B viral hepatitis. 8.Patients who have nontuberculous mycobacteril infection. 9.Patients who have congestive heart failure(>II).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number(%) of patients who developed in low disease activity from 12 to 52 weeks | — |
Countries
Japan
Contacts
Public ContactShigeto Kobayashi
Juntendo University, Juntendo Koshigaya Hopspital Rheumatology, Internal Medicine
Outcome results
None listed